BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

313 related articles for article (PubMed ID: 33509250)

  • 1. Development of a multi-gene-based immune prognostic signature in ovarian Cancer.
    Cao T; Shen H
    J Ovarian Res; 2021 Jan; 14(1):20. PubMed ID: 33509250
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Novel Immune-Related Prognostic Signature for Thyroid Carcinoma.
    Xue Y; Li J; Lu X
    Technol Cancer Res Treat; 2020; 19():1533033820935860. PubMed ID: 32588760
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification and verification of a ten-gene signature predicting overall survival for ovarian cancer.
    Liu J; Xu F; Cheng W; Gao L
    Exp Cell Res; 2020 Oct; 395(2):112235. PubMed ID: 32805252
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development and Validation of an Immune-Related Prognostic Signature for Ovarian Cancer Based on Weighted Gene Coexpression Network Analysis.
    An Y; Yang Q
    Biomed Res Int; 2020; 2020():7594098. PubMed ID: 33381581
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification of an energy metabolism‑related gene signature in ovarian cancer prognosis.
    Wang L; Li X
    Oncol Rep; 2020 Jun; 43(6):1755-1770. PubMed ID: 32186777
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of a glycolysis-related gene signature for survival prediction of ovarian cancer patients.
    Zhang D; Li Y; Yang S; Wang M; Yao J; Zheng Y; Deng Y; Li N; Wei B; Wu Y; Zhai Z; Dai Z; Kang H
    Cancer Med; 2021 Nov; 10(22):8222-8237. PubMed ID: 34609082
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A novel risk score system for assessment of ovarian cancer based on co-expression network analysis and expression level of five lncRNAs.
    Zhao Q; Fan C
    BMC Med Genet; 2019 Jun; 20(1):103. PubMed ID: 31182053
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Construction and validation of a transcription factors-based prognostic signature for ovarian cancer.
    Cheng Q; Li L; Yu M
    J Ovarian Res; 2022 Feb; 15(1):29. PubMed ID: 35227285
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development of a novel transcription factors-related prognostic signature for serous ovarian cancer.
    Li H; Wu N; Liu ZY; Chen YC; Cheng Q; Wang J
    Sci Rep; 2021 Mar; 11(1):7207. PubMed ID: 33785763
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Novel gene signatures for prognosis prediction in ovarian cancer.
    Bao M; Zhang L; Hu Y
    J Cell Mol Med; 2020 Sep; 24(17):9972-9984. PubMed ID: 32666642
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A novel tumor mutational burden-based risk model predicts prognosis and correlates with immune infiltration in ovarian cancer.
    Wang H; Liu J; Yang J; Wang Z; Zhang Z; Peng J; Wang Y; Hong L
    Front Immunol; 2022; 13():943389. PubMed ID: 36003381
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A nine-gene signature related to tumor microenvironment predicts overall survival with ovarian cancer.
    Ding Q; Dong S; Wang R; Zhang K; Wang H; Zhou X; Wang J; Wong K; Long Y; Zhu S; Wang W; Ren H; Zeng Y
    Aging (Albany NY); 2020 Mar; 12(6):4879-4895. PubMed ID: 32208363
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Profiles of immune infiltration in lung adenocarcinoma and their clinical significant: A gene-expression-based retrospective study.
    Chen G; Dong Z; Wu D; Chen Y
    J Cell Biochem; 2020 Nov; 121(11):4431-4439. PubMed ID: 32003059
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Potential Prognostic Immune Biomarkers of Overall Survival in Ovarian Cancer Through Comprehensive Bioinformatics Analysis: A Novel Artificial Intelligence Survival Prediction System.
    He T; Huang L; Li J; Wang P; Zhang Z
    Front Med (Lausanne); 2021; 8():587496. PubMed ID: 34109184
    [No Abstract]   [Full Text] [Related]  

  • 15. Multi-omics analysis of tumor mutational burden combined with prognostic assessment in epithelial ovarian cancer based on TCGA database.
    Liu J; Xu W; Li S; Sun R; Cheng W
    Int J Med Sci; 2020; 17(18):3200-3213. PubMed ID: 33173439
    [No Abstract]   [Full Text] [Related]  

  • 16. Identification and validation of an immune prognostic signature in colorectal cancer.
    Li M; Wang H; Li W; Peng Y; Xu F; Shang J; Dong S; Bu L; Wang H; Wei W; Hu Q; Liu L; Zhao Q
    Int Immunopharmacol; 2020 Nov; 88():106868. PubMed ID: 32771948
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of a prognostic gene signature based on an immunogenomic landscape analysis of bladder cancer.
    Luo Y; Chen L; Zhou Q; Xiong Y; Wang G; Liu X; Xiao Y; Ju L; Wang X
    J Cell Mol Med; 2020 Nov; 24(22):13370-13382. PubMed ID: 33048468
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A signature based on anoikis-related genes for the evaluation of prognosis, immunoinfiltration, mutation, and therapeutic response in ovarian cancer.
    Duan Y; Xu X
    Front Endocrinol (Lausanne); 2023; 14():1193622. PubMed ID: 37383389
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development and Validation of an Individualized Immune Prognostic Signature for Recurrent Prostate Cancer.
    Jin Y; Wang L; Lou H; Song C; He X; Ding M
    Comb Chem High Throughput Screen; 2021; 24(1):98-108. PubMed ID: 32593277
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development and verification of an immune-related gene pairs prognostic signature in ovarian cancer.
    Zhang B; Nie X; Miao X; Wang S; Li J; Wang S
    J Cell Mol Med; 2021 Mar; 25(6):2918-2930. PubMed ID: 33543590
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.